The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ARWR | +215.04% | -28.68% | -6.53% | +24% |
| S&P | +13.95% | +78.35% | +12.25% | +518% |
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
This biotech firm develops RNAi therapeutics for rare and serious diseases, leveraging clinical partnerships to advance its pipeline.
Arrowhead Pharmaceuticals, a leader in RNAi therapeutics, reported a significant insider sale amid a year of exceptional stock gains.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $264.03M | 10461.3% |
| Gross Profit | $257.64M | 9520.2% |
| Gross Margin | 97.58% | 207.0% |
| Market Cap | $9.02B | 285.4% |
| Market Cap / Employee | $12.68M | 0.0% |
| Employees | 711 | 16.7% |
| Net Income | $28.24M | 116.1% |
| EBITDA | $47.20M | 130.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $201.64M | 274.2% |
| Accounts Receivable | $218.87M | 8654.8% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $640.23M | -25.9% |
| Short Term Debt | $47.53M | 480.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 15.45% | 93.5% |
| Return On Invested Capital | -31.93% | 3.5% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $11.33M | 107.1% |
| Operating Free Cash Flow | $13.48M | 108.9% |
| Metric | Q4 2025 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 43.16 | - | |||
| Price to Book | 30.42 | 3.19 | 9.12 | 19.33 | 53.31% |
| Price to Sales | 3.14 | 3.83 | 5.64 | 8.56 | -99.09% |
| Price to Tangible Book Value | 35.99 | 3.23 | 9.25 | 19.62 | 48.42% |
| Price to Free Cash Flow TTM | 372.79 | 29.83 | 28.57 | - | |
| Enterprise Value to EBITDA | 3.50 | -12.60 | 89.76 | 192.95 | -1228.72% |
| Free Cash Flow Yield | 0.3% | 3.4% | 3.5% | - | |
| Return on Equity | -24.7% | -34.8% | -0.5% | 65.1% | -110.84% |
| Total Debt | $740.51M | $713.29M | $733.68M | $687.76M | -21.13% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
